key: cord-0785647-vk2pgidf authors: Goshua, George; Lee, Alfred Ian title: Harmonizing hypercoagulable heterogeneity: Baseline VTE risk in COVID‐19 date: 2021-01-20 journal: Res Pract Thromb Haemost DOI: 10.1002/rth2.12448 sha: 76ddd9a97c70e78b1e70c6e630cebcfdd42c4938 doc_id: 785647 cord_uid: vk2pgidf nan Thrombosis in coronavirus disease 2019 (COVID-19) is a multifactorial process resulting from contributions of endotheliopathy, platelet activation, activation of the coagulation cascade, and derangement in the fibrinolytic systemic in the backdrop of immune dysregulation. [1] [2] [3] Venous thromboembolism (VTE), arterial thrombosis, and microvascular thrombosis have all been described in hospitalized patients with COVID-19, particularly during critical illness. Due to concerns about heightened thrombosis risks, the clinical practice at several treating institutions has been to incorporate escalated-intensity anticoagulation for some patients while awaiting clinical trials data on the safety and efficacy of this approach. [4] [5] [6] [7] An important and surprising limitation of the current literature is that thrombosis rates in different published reports of COVID-19associated coagulopathy vary widely: Depending on the study, the reported prevalence of VTE in hospitalized patients with COVID-19 has been as low as 0% and as high as 85%. 8, 9 This heterogeneity likely reflects key differences among individual studies in a number of factors. One is disease severity, as different studies have variably included critically ill, hospitalized noncritically ill, or ambulatory patients. The studies have also differed in their approach to imaging, with some employing screening imaging modalities in all patients and others using a nonscreening, symptom-directed approach. Different studies have included different types of thrombotic events, with the country of origin of each study and resultant use (or nonuse) of anticoagulant prophylaxis likely further impacting thrombosis rates in the various published reports. Stephan Nopp and colleagues provide a comprehensive synthesis of data from all over the world on the risk of VTE in hospitalized patients with COVID-19, excluding studies with a high degree of bias. 10 In their meta-analysis, they analyzed a total of 28 173 patients from 66 studies originating in Europe, North America, and Asia, examining thrombosis rates in studies that incorporated either screening or nonscreening imaging. The overall VTE rates including both screening and nonscreening approaches were 22.7% (18.1%-27.6%) in the intensive care unit (ICU) setting and 7.9% (5.1%-11.2%) in the non-ICU setting. Among screening imaging studies in the ICU and non-ICU settings, VTE rates were 45.6% (30.6%-61.1%) and 23.0%; with a nonscreening approach, these were 18.7% (14.9%-22.9%) and 5.5% (3.6%-7.9%), respectively. In comparison to historical studies of patients without COVID-19, the compiled VTE rates in patients with COVID-19 in the ICU on pharmacologic thromboprophylaxis are higher, while the VTE risk in non-ICU patients is at least comparable. [11] [12] [13] This is particularly relevant considering that no major organization currently recommends more than prophylactic antico- higher-quality studies become available. On a societal level, cost effectiveness analyses of the varied anticoagulation practices implemented at different institutions and their impact on thrombosis, bleeding, and mortality rates will need to be explored, particularly in the subset of patients with COVID-19 who develop persistent aftereffects of this diagnosis. Understanding all of these factors will ideally enable clinicians to develop customized, case-by-case assessments of efficacy and safety of increased-intensity anticoagulation in the prevention of VTE in hospitalized patients with COVID-19. GG and AIL wrote and edited the invited editorial commentary. The authors declare no conflicts of interest. Platelet gene expression and function in COVID-19 patients Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study Neutrophil extracellular traps (NETs) Contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome clinical trial registration information (if any) Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19 ISTH interim guidance on recognition and management of coagulopathy in COVID-19: a comment Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Extremely high incidence of lower extremity deep venous thrombosis in 48 patients with severe COVID-19 in Wuhan Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis Electronic alerts to prevent venous thromboembolism among hospitalized patients Adjunctive intermittent pneumatic compression for venous thromboprophylaxis A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report Antithrombotic Therapy in Patients with COVID-19 Treatment Guidelines Guidelines on Use of Anticoagulation in Patients with COVID-19 ISTH interim guidance on recognition and management of coagulopathy in COVID-19